大脑静脉血栓症:当前的治疗,最近的进展和未来的方向
Jelle Vellema1, Anita van de Munckhof1, Jonathan M Coutinho1
1Department of Neurology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.
概括
大脑静脉血栓 (CVT) 是中风的重要原因,特别是在年轻人中. 目前的治疗方法包括抗凝药,在严重的情况下,内血管治疗,正在研究改进诊断和新疗法.
科学领域:
- 神经学 神经学
- 血管医学 血管医学
- 脑卒中研究 脑卒中研究
背景情况:
- 大脑静脉血栓 (CVT) 是不常见但重要的中风原因,主要影响年轻人.
- 持续培训可能导致严重的残疾和死亡率,需要有效的管理策略.
研究的目的:
- 审查目前的CVT治疗策略.
- 总结最近在CVT诊断和管理方面的进展.
- 探索CVT研究和护理的潜在未来方向.
主要方法:
- 审查关于CVT治疗和进展的当前文献.
- 对最近的研究进行分析,包括DECOMPRESS2试验.
- 讨论新的诊断工具和治疗方法.
主要成果:
- 抗凝剂是CVT的主要治疗方法,直接口服抗凝剂 (DOAC) 显示出与维生素K对抗剂 (VKA) 相当的安全性和有效性.
- 内血管治疗是严重,耐火病例的选择,尽管随机试验的证据有限.
- 新的评分系统有助于预测CVT患者的和长期结果.
结论:
- 需要通过临床决策规则和生物标志物改善诊断工作.
- 人工智能有可能在成像上更早检测CVT.
- 新型抗凝剂和纤维溶解疗法为重新道化提供了希望.
- 多中心研究和国际合作对于推进继续培训护理和减少其全球负担至关重要.
相关概念视频
Venous Thrombosis III: Interprofessional Care
271
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
271
Venous Thrombosis IV: Nursing Management
190
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
190
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
280
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
280
Venous Thrombosis I: Introduction
334
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
334
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
293
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
293
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K


